依立雄胺治疗前列腺增生临床疗效的Meta分析  

Curative effect of epristeride in the treatment of chronic prostatic hyperplasia: a meta- analysis

作　　者：谢子平[1] 谭艳[1] 谢胜[1] 王万荣[1] 李韬[1] 

机构地区：[1]湖北医药学院附属人民医院男科,湖北十堰442000

出　　处：《中国性科学》2015年第12期35-43,共9页Chinese Journal of Human Sexuality

摘　　要：目的:探讨依立雄胺治疗前列腺增生的疗效评价。方法:通过检索自1994年1月至2014年1月期间英国医学会电子全文期刊数据库(BMA)、荷兰医学文摘数据库(EMbase)、学术期刊集成全文数据库(ASP)、考克兰图书馆(The Cochrane Library)、西文生物医学期刊文献数据库(EMCC)、美国国立医学图书馆生物医学信息检索系统(Pubmed)、万方数据库(CECDB)、维普中文科技期刊全文数据库(CQVIP)、中文科技期刊数据库(VIP)、中国生物医学文献数据库(CBM)、中国学术期刊全文数据库(CNKI)等数据库内相关的随机对照试验(RCT),对纳入文献的质量进行严格评价和资料提取,使用Stata/SE version 12.0软件对纳入研究进行Meta分析。结果:最终纳入8篇RCT,共791例患者,其中实验组患者406例、对照组患者385例。实验组患者予以依立雄胺、对照组予以非那雄胺。Meta分析结果显示:相比非那雄胺,前列腺良性增生患者应用依立雄胺,可有效降低患者的国际前列腺症状评分[P=0.361、I2=8.9%、SMD=-0.24、95%CI=(-0.38,-0.10)],结果稳健[bias_p=0.995、bias_95 CI=(-2.918712,2.934377)];提升最大尿流率[P=0.025、I2=56.2%、SMD=0.33、95%CI=(0.19,0.47)],结果稳健[bias_p=0.502、bias_95 CI=(-1.570141,2.865725)];但对于患者的前列腺体积,meta分析显示两种药物的作用未见显著差异性。结论:相比非那雄胺,应用依立雄胺可有效降低前列腺良性增生患者的国际前列腺症状评分、提升最大尿流率,从而改善患者的临床症状,其疗效确切,值得临床推广。Objectives： To investigate the effect of epristeride in the treatment of chronic prostatic hyperplasi- a. Methods： The RCTs in the PubMed, BMA, EMbase, ASP, the Cochrane Library, EMCC, CBM, CNKI, CEC- DB, CQVIP, V1P database from January 1994 to January 2014 were searched. Strict appraisal and data extraction on the quality of the included studies was conducted, and meta - analysis was done using Stata/SE version 12 software systematic evaluation of included studies. Results： 8 articles on RCT were included, a total of 791 patients, including 406 patients in the experimental group and 385 control group patients. The experimental group received epristeride, and control group were given finasteride. Meta - analysis showed that compared with finasteride, benign prostatic hy- perplasia patients using pristerlde, could effectively reduce the international prostate symptom score [ P = 0. 361, 12 = 8.9%, SMD = - 0.24, 95% CI = （ - 0.38, - 0. 10） ], with robust results [bias_p = 0.995, bias_95 CI = （ -2. 918712, 2.934377） ] ; and increase the maximum urinary flow rate [P=0. 025, 12 =56.2% and SMD =0. 33, 95%CI = （0. 19, 0. 47） ], with robust results [bias_p =0. 502, bias_95 C1 = （ - 1.570141, 2.865725） ] ; but for the patients with prostate volume, meta- analysis showed no significant differences between the two drugs. Conclu- sion ： Compared with finasteride, application of epristeride can effectively reduce the International Prostatic Symptom Score of patients with benign prostatic hyperplasia and improve the maximal urinary flow rate, thereby improving the clinical symptoms of patients. With correct curative effect, it is worth clinical promotion.

关 键 词：依立雄胺 非那雄胺 良性前列腺增生症 5-Α还原酶抑制剂 META分析 

分 类 号：R697.3[医药卫生—泌尿科学]